Work

A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps3104

Authors: Partow Kebriaei, Christopher Austin Klebanoff, Ben C. Creelan, David S. Hong, George R. Blumenschein, Alexandra Drakaki, Ashutosh Tewari, Lisa Thomrongsith, Yizhou Jiang, Rajul K. Jain

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, University of California, Los Angeles

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891381367

Cites:

Cited by: 1

Related to: 10